Abstract The Royal Australian and New Zealand College of Psychiatrists (RANZCP) is
coordinating the development of clinical practice guidelines (CPGs) in psychiatry, funded …

Objective: To determine if the inclusion of a placebo arm and/or the number of active
comparators in antidepressant trials influences the response rates of the active medication …

Objective: To evaluate the efficacy and safety of a selective serotonin reuptake inhibitor
(SSRI) and a serotonin and norepinephrine reuptake inhibitor (SNRI) in the treatment of …

Major depression is a heterogeneous condition, and the search for neural correlates specific
to clinically defined subtypes has been inconclusive. Theoretical considerations implicate …

Background The type and quantities of antidepressants are increasing, but the efficacy and
safety of first-line and emerging drugs vary between studies. In this article, we estimated the …

Background: Clinicians and researchers synthesize data from randomized controlled trials
(RCTs) of antidepressants to make conclusions about the efficacy of medications for …

Objective Meta-analysis of all available trials of Venlafaxine in the treatment of major
depressive disorders, including treatment resistant depression and long-term relapse …

Objective: To summarize remission rates and dropouts due to adverse drug reactions
(ADRs) or lack of efficacy (LoE) of serotonin-norepinephrine reuptake inhibitors (SNRIs) …

Schueler Y‐B, Koesters M, Wieseler B, Grouven U, Kromp M, Kerekes MF, Kreis J, Kaiser T,
Becker T, Weinmann S. A systematic review of duloxetine and venlafaxine in major …

Third-generation antidepressants are a group of antidepressant agents of variable action,
not confined to serotonin reuptake inhibition. These agents include venlafaxine, reboxetine …